In this episode, Tom Caravela welcomes Steve St. Onge to discuss the intricacies of corporate acquisitions within the pharmaceutical industry. Steve shares his journey through corporate development and provides insight into the transition and management of acquisitions, both before and after announcements. The conversation delves into the emotional and strategic aspects of navigating acquisitions, identifying warning signs, and the impact of market volatility. Steve offers practical advice for decision-making during economic downturns and strategies for embracing change and new opportunities in the pharma sector. The episode concludes with a discussion on future innovation and optimism in biotech, along with closing remarks and gratitude to listeners.
Steve St. Onge, Sr Director Business Development and Corporate Communications at Paratek discusses what to expect after your company has been acquired.
Steve shares….
👉 What to expect when acquisition news hits
👉 How to handle emotions and not panic
👉 What steps you should take after acquisition news
👉 What are the warning signs to be aware of
👉 Why is the pharma / biotech sector so volatile these days
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Karen Geary
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret
Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys